Find clinical trials for Colon Cancer in Sevilla, AN
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Colon Cancer trials near Sevilla, AN, ESP:
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Seville, Spain and 262 other locations
and pembrolizumab) given together for the treatment of colorectal cancer that:* is metastatic (spread to other parts of the body);* has the ...
Phase 2
Seville, Spain and 61 other locations
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor...
Phase 1
Seville, Spain and 63 other locations
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patie...
Phase 1, Phase 2
Seville, Spain and 55 other locations
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon...
Phase 3
Jerez de la Frontera, Cádiz, Spain and 307 other locations
with standard chemotherapy for the potential treatment of colorectal cancer that:* has spread to other parts of the body (metastatic);* has ...
Phase 3
Seville, Spain and 274 other locations
tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer....
Phase 2
Seville, Spain and 88 other locations
The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bev...
Phase 3
Seville, Spain and 189 other locations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...
Phase 1
Seville, Spain, Spain and 50 other locations
without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer...
Phase 1, Phase 2
Seville, Spain and 48 other locations
Clinical trials
Research sites
Resources
Legal